10 June 2020
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 50,013 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under The 2017 Clinigen Group Sharesave Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 15 June 2020.
At admission the issued share capital of the Group will consist of 132,898,771 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 132,898,771. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
|
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
|
Shaun Chilton, Group Chief Executive Officer |
|
|
Nick Keher, Group Chief Financial Officer |
|
|
Matt Parrish, Head of Investor Relations |
|
|
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker |
Tel: +44 (0) 20 7260 1000 |
|
James Mitford / Hemant Kapoor |
|
|
|
|
|
RBC Capital Markets - Joint Broker |
Tel: +44 (0) 20 7653 4000 |
|
Marcus Jackson / Elliot Thomas |
|
|
|
|
|
Instinctif Partners |
Tel: +44 (0) 20 7457 2020 |
|
Melanie Toyne-Sewell / Phillip Marriage |
Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
